{"id":"b93e97c2-8c6b-5792-bd6d-3a69539f4f82","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-mmi30","predicate":"promotes_normalization_of","statement":"At two weeks, FT4 normalized in 59% with MMI 30 mg plus KI versus 29% with MMI alone.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"605a94e8-b13d-55e1-abb6-28ede23b730e","mechanism_event_label":"KI accelerated early control alongside methimazole.","subject":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"object":{"id":"5554c435-1309-5f33-bf47-6cf03cdff963","slug":"serum-free-t4-concentration","display_name":"Serum free thyroxine concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"605a94e8-b13d-55e1-abb6-28ede23b730e","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-mmi30-event","event_type":"observed_relationship","label":"KI accelerated early control alongside methimazole.","description":"At two weeks, FT4 normalized in 59% with MMI 30 mg plus KI versus 29% with MMI alone.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5554c435-1309-5f33-bf47-6cf03cdff963","slug":"serum-free-t4-concentration","display_name":"Serum free thyroxine concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a3a516d1-65de-5638-8baa-bf4571450959","slug":"methimazole","display_name":"Methimazole","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure_category","value_text":"Study-specific exposure, including pharmacological and in-vitro conditions; normal is the schema fallback outside the three availability categories.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Combination treatment, not KI monotherapy; KI dose not extracted from abstract. Faster biochemical control does not prove lasting remission.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Potassium iodide research collection; shared-anion and comparator studies are not all KI interventions.","comparator":null,"unit":null,"notes":"","entity":{"slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"KI accelerated early control alongside methimazole.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. · 2010 · https://pubmed.ncbi.nlm.nih.gov/19912243/ · DOI 10.1111/j.1365-2265.2009.03745.x","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"bad51330-02d9-5cc4-98ec-63c8ff4747a7","evidence_kind":"source_excerpt","locator":"Lines 384-390","start_line":384,"end_line":390,"excerpt":"## ki-mmi30\nKI accelerated early control alongside methimazole.\nAt two weeks, FT4 normalized in 59% with MMI 30 mg plus KI versus 29% with MMI alone.\nModel: 134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.\nLimitations: Combination treatment, not KI monotherapy; KI dose not extracted from abstract. Faster biochemical control does not prove lasting remission.\nEvidence location: Primary abstract\nBenefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. · 2010 · https://pubmed.ncbi.nlm.nih.gov/19912243/ · DOI 10.1111/j.1365-2265.2009.03745.x","model_system":"134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curation paraphrase; primary evidence location and source kind retained above.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dc3ce411-f68f-5eb8-87c1-1592665f9cb6","stable_key":"import-79018983-9179-5c1a-8e7a-d6f47a13582b","title":"Potassium iodide: thyroid and non-thyroid mechanisms, interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-study references, chemical references and label statements individually identified. Not publisher full text.","file_path":"","sha256":"3ff9da818dd7a763a59c6abcff2eaee136d7f887a777034feaa5ba304a8fa6ce","revision_id":"53f2ae88-8a91-5326-ac49-3bb510ca78c3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}